Results 61 to 70 of about 218,137 (295)
Human T cell glycosylation and implications on immune therapy for cancer [PDF]
, 2020 Glycosylation is an important post-translational modification, giving rise to a diverse and abundant repertoire of glycans on the cell surface, collectively known as the glycome.
Callewaert, Nico +3 more
core +1 more source
FEBS Letters, EarlyView.Plasma membranes contain dynamic nanoscale domains that organize lipids and receptors. Because viruses operate at similar scales, this architecture shapes early infection steps, including attachment, receptor engagement, and entry. Using influenza A virus and HIV‐1 as examples, we highlight how receptor nanoclusters, multivalent glycan interactions ...
Jan Schlegel, Christian Sieben
wiley +1 more source
Posttranslational Modifications in PD-L1 Turnover and Function: From Cradle to Grave
Biomedicines, 2021 Programmed death-ligand 1 (PD-L1) is one of the most classic immune checkpoint molecules. Cancer cells express PD-L1 to inhibit the activity of effector T cells’ cytotoxicity through programmed death 1 (PD-1) engagement in exposure to inflammatory ...
Xinfang Yu +3 more
doaj +1 more source
Anti program death-1/anti program death-ligand 1 in digestive cancers
World Journal of Gastrointestinal Oncology, 2015 Human tumors tend to activate the immune system regulatory checkpoints as a means of escaping immunosurveillance. For instance, interaction between program death-1 (PD-1) and program death-ligand 1 (PD-L1) will lead the activated T cell to a state of anergy. PD-L1 is upregulated on a wide range of cancer cells.
Eléonore, de Guillebon +3 more
openaire +2 more sources
The roles of programmed death ligand 1 in virus-associated cancers
Infection, Genetics and Evolution, 2020 Programmed death ligand 1 (PD-L1) is a surface glycoprotein that induces T-cell anergy or apoptosis by binding to PD-1 on activated T and B cells. It is also known as a cluster of differentiation 274 (CD274) or B7 homolog 1 (B7-H1). Suppressing the adaptive arm of the immune system is the critical role of PD-L1.so it prohibits the proliferation of ...
Morvarid, Golrokh Mofrad +2 more
openaire +2 more sources
Potential therapeutic targeting of BKCa channels in glioblastoma treatment
Molecular Oncology, Volume 20, Issue 6, Page 1398-1419, June 2026.This review summarizes current insights into the role of BKCa and mitoBKCa channels in glioblastoma biology, their potential classification as oncochannels, and the emerging pharmacological strategies targeting these channels, emphasizing the translational challenges in developing BKCa‐directed therapies for glioblastoma treatment.
Kamila Maliszewska‐Olejniczak +4 more
wiley +1 more source
PD-L1 and PD-1 in immune regulation and their implications in blood cancers
Advances in Cancer Biology - MetastasisBecause of emerging opportunities for cancer immunotherapy, the capacity to suppress the immune system in order to cure and eradicate cancer is currently a topic of intense study.
Parisa Shiri Aghbash +7 more
doaj +1 more source
Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells
Frontiers in Immunology, 2017 The programmed death-1 (PD-1) and its ligand PD-L1 (B7-H1) signaling pathway has been the focus of much enthusiasm in the fields of tumor immunology and oncology with recent FDA approval of the anti-PD-1 antibodies pembrolizumab and nivolumab and the ...
Rachel M. Gibbons Johnson +2 more
doaj +1 more source
D-1 / PD-L1 EXPRESSION IN INVASIVE BREAST CARCINOMA / CANCER
Pakistan Armed Forces Medical Journal, 2021 Objective: To investigate the immunohistochemical expression of PD-1 and PD-L1 in breast cancer cases and its correlation with clinicopathological factors. Study Design: Cross sectional study. Place and Duration of Study: Histopathology department,
Sammeen Salim +3 more
doaj +1 more source
Programmed Death Ligand-1 Immunohistochemistry: Friend or Foe? [PDF]
Archives of Pathology & Laboratory Medicine, 2016 The approval of anti-programmed death receptor (PD)-1 therapies for non–small cell lung cancer has directed the spotlight on programmed death ligand-1 (PD-L1) immunohistochemistry as the latest predictive biomarker potentially required in this disease.
Keith M, Kerr, Fred R, Hirsch
openaire +2 more sources